Stem cell therapy or hair regeneration has been the buzz word in the hair loss community for some years now. It is our collective hope that stem cell therapy for hair loss will provide better solutions for people with thinning or balding hair.
Over the years there has been two main companies conducting extensive research into this area - Aderans Research Institute (ARI) and Intercytex ( or Regenerative Medicine Assets Limited). Both have spent millions of dollars in research and development into this technology. However, it was unfortunate to learn that Intercytex closed it's doors a few months ago. The next question was "what will happen to all of the research that Intercytex has done in this field?" That question has now been answered; Aderans has purchased their proprietary knowledge. In a press release from Aderans Research Institute the following comments were made:
"By acquiring the scientific assets of one of its chief competitors, ARI has further solidified its position as the leading research company in the hair regeneration industry."
"This acquisition is a major step forward for ARI," said Vern Liebmann, Vice President, Operations. "Through this deal, we've been able to consolidate the majority of key patents and know-how in the hair regeneration field, an achievement that can accelerate our ability to deliver a commercially viable product to market.
The deal comes as ARI is extending its Phase 2 clinical study of cell-based hair regeneration, in which it recently treated the trial's 100th subject. "We've acquired important proprietary knowledge that includes Intercytex's clinical efforts to date," noted Ken Washenik, MD PhD, Executive Vice President. "This information should substantially augment our efforts to create a viable cell-based solution for hair loss."
We look forward to what this consolidation in knowledge may mean for people across the world who suffer from hair loss, alopecia and thinning hair.